GlassScriptPhysician profile
Aarthi Rajkumar
NPI 1063790053
$2,222.44
in general payments reported to CMS, 2019-2025
33 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $183 · 2022: $415 · 2023: $1,016 · 2024: $418 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,581 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,581.38 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $304.41 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $237.45 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $200.04 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $115.32 | 2023-2025 | Enhertu, Lynparza, Calquence |
| Amgen INC. | $103.49 | 2022-2023 | Lumakras, Xgeva, Nplate |
| Takeda Pharmaceuticals U.S.A., INC. | $91.03 | 2021-2024 | Iclusig, Alunbrig |
| Alexion Pharmaceuticals, INC. | $91.02 | 2021-2024 | Ultomiris |
| Incyte Corporation | $84.05 | 2021-2024 | Jakafi |
| Merck Sharp & Dohme LLC | $81.06 | 2023 | Keytruda, Lynparza, Welireg |
| Genmab U.S., INC. | $79.98 | 2021-2024 | Tivdak |
| Genentech USA, INC. | $77.26 | 2023 | Hemlibra |
| Genzyme Corporation | $76.68 | 2022-2024 | |
| Seagen INC. | $71.89 | 2021-2023 | Tukysa |
| Foundation Medicine, INC. | $68.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $60.00 | 2021-2023 | Opdualag |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $54.19 | 2023-2025 | |
| Abbvie INC. | $52.46 | 2024-2025 | |
| Morphosys, US INC. | $45.19 | 2022-2023 | Monjuvi |
| Beigene USA, INC. | $41.69 | 2022-2023 | Brukinsa |
| Celgene Corporation | $39.40 | 2022-2023 | Reblozyl |
| Array Biopharma INC | $32.70 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $22.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.59 | 2022 | |
| Gilead Sciences, INC. | $21.25 | 2023 | Trodelvy |
| Daiichi Sankyo INC. | $20.77 | 2024 | Enhertu |
| Lilly USA, LLC | $20.50 | 2021 | |
| Blueprint Medicines Corporation | $19.81 | 2024 | Ayvakit |
| Kite Pharma, INC. | $16.46 | 2023 | Yescarta |
| Janssen Pharmaceuticals, INC | $16.09 | 2022 | |
| Adc Therapeutics America, INC. | $15.33 | 2024 | |
| Springworks Therapeutics, INC. | $13.79 | 2024 | Ogsiveo |
| Bayer Healthcare Pharmaceuticals INC. | $13.63 | 2021 | |
| Verity Pharmaceuticals INC. | $13.41 | 2024 | Trelstar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aarthi Rajkumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.